Rheumatology

Newly Created Viatris Joins the Biosimilars Forum

November 30, 2020

Tony Hagen

Article

The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach.

Alvotech Scientific Officer Describes Company's Global Biosimilars Strategy

November 25, 2020

Tony Hagen

Article

Joseph E. McClellan, PhD, MBA, discussed navigation of regulatory hurdles as the company continues its quest to line up distribution partnership deals across the globe.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

November 24, 2020

Skylar Jeremias

Article

Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

Opinion: Embrace the Era of Next-Generation Biologics

November 21, 2020

Bincy P. Abraham, MD

Article

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.

Alvotech Files for US and EU Approval of Adalimumab Biosimilar

November 20, 2020

Tony Hagen

Article

The rheumatology and gastroenterology biosimilar candidate would enter the lucrative market established by Humira.

High Patient Retention Observed for Multiple Etanercept Switches

November 16, 2020

Tony Hagen

Article

Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.

IGBA Launches Global Biosimilars Week

November 16, 2020

Tony Hagen

Article

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

High Adherence Noted Among Infliximab Biosimilar Users

November 16, 2020

Tony Hagen

Article

Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.

US Rheumatologists Understand and Accept Biosimilars, but Some Hesitation Remains

November 13, 2020

Deana Ferreri, PhD

Article

Samsung Launches Clinical Study of Denosumab Candidate

November 10, 2020

Tony Hagen

Article

The company is targeting the lucrative osteoporosis market dominated by Prolia, an Amgen product.

x